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background: Vasodilators are commonly used acutely to treat severe mitral regurgitation (SMR) with left ventricular (LV) dilation. They increase the 
forward stroke output, reduce the regurgitant volume and decrease pulmonary venous pressure. There is a paucity of data on chronic use of nitrates 
in SMR with no LV dilation. The aim of this study was to determine the effect of using vasodilators on mortality of patients with SMR who have normal 
LV function and are not surgical candidates.
methods: From 2002 to 2012, transthoracic echos were reviewed to identify patients with SMR by color flow Doppler. Patients with normal LV 
function were included, defined by an ejection fraction >45% and a left ventricle diastolic dimension of <57 mm. Patients who had mitral valve 
repair were excluded. Subjects were divided into two groups: 1) Treatment group, patients treated with hydralazine and/or nitrates, and 2) No 
treatment group, patients who did not receive treatment with hydralazine and/or nitrates. Records of inpatient and social security deaths were used 
to determine 1-year mortality.
results… The study included 566 patients (mean age 73; 71% female). One year death rates in the Treatment group and No treatment group were 
23.9% and 28.5% respectively (p=0.422). Relative risk of no-therapy compared to therapy was 1.3 (95% CI 0.7-2.4).
conclusion:Chronic vasodilator therapy with hydralazine and/or nitrates does not provide a mortality benefit in patients with SMR who have 
normal LV function and are not surgical candidates.
